Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Arlene Soberano

Infectious Disease Chapel Hill, NC Medical Doctor

NPI 1750470456 CMS profile 306234

101 Manning Dr, Chapel Hill, NC 27514

Open in the dashboard

General payments

$19,419

29 records reported · program years 2019–2024

Research payments

$1,327

Paid to them · 17 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$43,478 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Arlene Soberano of Chapel Hill, NC is reported in the CMS Open Payments database as having received $19,419 across 29 general payments and $1,327 in research payments paid to them. Separately, studies naming them as principal investigator received $43,478 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $8,820 10
2023 General $1,615 4
2022 General $20 1
2019 General $8,965 14
2019 Research $1,327 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arlene Soberano
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Arlene Soberano were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Arlene Soberano Infectious Disease median Middle half National median
2019 $8,965 $190 $60–$862 $163
2020 $0 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $20 $166 $50–$834 $149
2023 $1,615 $171 $57–$787 $160
2024 $8,820 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Gen-Probe Sales & Service, Inc. $6,633 5 payments
  2. Gen-Probe, Inc. $4,745 2 payments
  3. Lupin Inc. $2,352 10 payments
  4. La Jolla Pharmaceutical Company $2,244 4 payments
  5. Hologic, LLC $1,830 4 payments
  6. Moderna TX, Inc. $1,615 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $10,666 3 payments
  2. Travel and Lodging $5,406 13 payments
  3. Food and Beverage $1,740 12 payments
  4. Honoraria $1,608 1 payment
Products named General payments · program years 2019–2024
  1. Aptima $5,404 4 payments
  2. SOLOSEC $2,352 10 payments
  3. Aptima M genitalium $613 2 payments
  4. PANTHER FUSION $79 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $1,327 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Infectious Disease: 268

Drug cost

$10,186

Median for Infectious Disease: $217,595

Branded share of claims

0%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fosfomycin Tromethamine Generic 18 $10,186

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$15,058

Medicare's payments for the services billed

Medicare patients

63

Average age 65

Services billed

164

32 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 70%
Ischemic heart disease 57%
Diabetes 51%
Heart failure 51%
Atrial fibrillation 48%
Arthritis 44%
Depression 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record